Positive list system may not save NHI finance.

Published: 2006-07-06 07:00:00

Updated: 2006-07-06 07:00:00

The pharmaceutical industry suggested a way of better NHI financial saving than the positive list system, which included more patient's own payment for minor disease treatments, reclassification of the prescription and non-prescription drugs and more tough NHI drug price approval system.

Accor...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK